Abstract 2118P
Background
The refeeding syndrome is a potentially lethal condition, associated with metabolic alterations after food reintroduction, and subsequent increase in nutritional intake. It occurs especially in malnourished patients, or in a hyper-catabolic stage. Particularly oncological diseases represent an increased risk factor for the manifestation of the syndrome. Data related to the oncological population is rarely reported, except for the various case series/case studies published to date.This study aims to determine the prevalence of refeeding syndrome in oncological patients according to their risk and to develop a clinical pathway to address and monitor this syndrome.
Methods
A prospective longitudinal study was carried out on 124 patients who started exclusive support via parenteral or enteral nutrition, in 4 units of the oncology hospital: intensive care, intermediate care, medical and surgical inpatient units. Risk for refeeding syndrome was determined as follows: low risk, moderate, high. Biochemistry available (ionogram) before feeding, and its evolution over the first 5 days after initiation was evaluated.
Results
In 64% of patients, serum phosphate, potassium, and magnesium measurements were available prior to nutritional support. There was no information on serum phosphate in 29.7% of patients, with no significant differences between surgical and medical patients. After 48 hours, serum concentration variations were especially pronounced in patients without electrolyte supplementation prior to feeding (-18.2%) versus previously supplemented (10.3%) (p=0.035). After 72 hours, 31.8% of patients experienced reductions superior to 30% in the ionogram, compatible with refeeding syndrome. A positive Spearman's correlation (0.69, p=0.017) was identified between the initially assessed risk (moderate and high) and the decrease in phosphate (>20%) observed at the end of 48 hours in non-supplemented patients.
Conclusions
There is a high prevalence of refeeding syndrome in cancer patients. Monitoring should be continuous, including hypophosphatemia. By providing a multidisciplinary intervention and allowing the provision of micronutrients at the appropriate time, complications of the syndrome can be avoided.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Instituto Português de Oncologia do Porto Francisco Gentil (IPO).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06